In this randomized, open-label, 2-part, 2 × 2 crossover, phase 1 study, the effect of a low-fat low-calorie (LFLC) meal on the relative bioavailability of a trametinib 2-mg tablet or dabrafenib 150-mg capsule was evaluated in healthy participants. Trametinib adjusted geometric mean ratios (90%CI) of fed : fasted for area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration and AUC from time 0 extrapolated to infinity were 0.76 (0.71-0.82) and 0.82 (0.77-0.88), respectively. For dabrafenib, the adjusted geometric mean ratios of AUC from time 0 to the last quantifiable concentration and AUC from time 0 extrapolated to infinity (90%CI) for fed:fasted were 0.85 (0.79-0.91) and 0.86 (0.80-0.92), respectively. Consumption of an LFLC meal delayed trametinib and dabrafenib absorption, with an increase in time to maximum concentration of ≈15 and ≈30 minutes, respectively, compared to the fasted state. These findings indicate that consumption of an LFLC meal reduced the bioavailability and delayed the absorption of trametinib and dabrafenib, supporting current recommendations to administer both drugs in the fasting state; however, an occasional LFLC meal is unlikely to affect the pharmacokinetics of the drugs once steady state is reached and, by consequence, not likely to alter the overall intended efficacy.

Novartis Healthcare Private Limited Hyderabad India

Novartis Institute of Biomedical Research Inc Cambridge Massachusetts USA

Novartis Pharmaceuticals Corporation East Hanover New Jersey USA

Novartis Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc23003965

003      

CZ-PrNML

005      

20230425141019.0

007      

ta

008      

230418s2023 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1002/cpdd.1220 $2 doi

035    __

$a (PubMed)36662829

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Tan, Eugene Y $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

245    10

$a Evaluation of a Low-Fat Low-Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open-Label, 2-Part Study in Healthy Participants / $c EY. Tan, M. Pazdirkova, AJ. Taylor, N. Singh, GR. Iyer

520    9_

$a In this randomized, open-label, 2-part, 2 × 2 crossover, phase 1 study, the effect of a low-fat low-calorie (LFLC) meal on the relative bioavailability of a trametinib 2-mg tablet or dabrafenib 150-mg capsule was evaluated in healthy participants. Trametinib adjusted geometric mean ratios (90%CI) of fed : fasted for area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration and AUC from time 0 extrapolated to infinity were 0.76 (0.71-0.82) and 0.82 (0.77-0.88), respectively. For dabrafenib, the adjusted geometric mean ratios of AUC from time 0 to the last quantifiable concentration and AUC from time 0 extrapolated to infinity (90%CI) for fed:fasted were 0.85 (0.79-0.91) and 0.86 (0.80-0.92), respectively. Consumption of an LFLC meal delayed trametinib and dabrafenib absorption, with an increase in time to maximum concentration of ≈15 and ≈30 minutes, respectively, compared to the fasted state. These findings indicate that consumption of an LFLC meal reduced the bioavailability and delayed the absorption of trametinib and dabrafenib, supporting current recommendations to administer both drugs in the fasting state; however, an occasional LFLC meal is unlikely to affect the pharmacokinetics of the drugs once steady state is reached and, by consequence, not likely to alter the overall intended efficacy.

650    _2

$a lidé $7 D006801

650    _2

$a biologická dostupnost $7 D001682

650    _2

$a zdraví dobrovolníci pro lékařské studie $7 D064368

650    12

$a omezení příjmu potravy $7 D005215

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a klinické zkoušky, fáze I $7 D017426

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Pazdirkova, Marketa $u Novartis, Prague, Czech Republic

700    1_

$a Taylor, Amanda J $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

700    1_

$a Singh, Namrata $u Novartis Healthcare Private Limited, Hyderabad, India

700    1_

$a Iyer, Ganesh R $u Novartis Institute of Biomedical Research Inc., Cambridge, Massachusetts, USA

773    0_

$w MED00184901 $t Clinical pharmacology in drug development $x 2160-7648 $g Roč. 12, č. 3 (2023), s. 333-342

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36662829 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230418 $b ABA008

991    __

$a 20230425141015 $b ABA008

999    __

$a ok $b bmc $g 1924559 $s 1190174

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 12 $c 3 $d 333-342 $e 20230120 $i 2160-7648 $m Clinical pharmacology in drug development $n Clin. pharmacol. drug dev. $x MED00184901

LZP    __

$a Pubmed-20230418